On July 29, 2026, a Nasdaq Hearings Panel granted the company an exception to continue its Nasdaq listing related to the $1.00 minimum bid price rule (Rule 5550(a)(2)). Genprex must demonstrate compliance by July 29, 2026 and then maintain a closing bid of at least $1.00 for each trading day through December 7, 2026 under Panel monitoring. Failure to meet these terms or other listing requirements could result in delisting.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.